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Mitochondrial dysfunction is a common feature in
neurodegeneration and aging. We identify mitochon-
drial dysfunction in xeroderma pigmentosum group
A (XPA), a nucleotide excision DNA repair disorder
with severe neurodegeneration, in silico and in vivo.
XPA-deficient cells show defective mitophagy with
excessive cleavage of PINK1 and increased mito-
chondrial membrane potential. The mitochondrial
abnormalities appear to be caused by decreased
activation of the NAD+-SIRT1-PGC-1a axis triggered
by hyperactivation of the DNAdamage sensor PARP-
1. This phenotype is rescued by PARP-1 inhibition
or by supplementation with NAD+ precursors that
also rescue the lifespan defect in xpa-1 nematodes.
Importantly, this pathogenesis appears common to
ataxia-telangiectasia and Cockayne syndrome, two
other DNA repair disorders with neurodegeneration,
but absent in XPC, a DNA repair disorder without
neurodegeneration. Our findings reveal a nuclear-
mitochondrial crosstalk that is critical for the main-
tenance of mitochondrial health.
INTRODUCTION
Althoughsignificantadvanceshavebeenmade inourunderstand-
ing of many DNA repair disorders, it remains an ongoing mystery
in the field of aging and DNA metabolism why some patients
with DNA repair deficiency develop neurodegeneration, whereas
others are spared. Accumulation of nuclear DNA damage has
been associated with accelerated aging disorders and normal
aging; however, theconnectionbetweenDNAdamageandneuro-
degeneration is less clear (Hoeijmakers, 2009; Rass et al., 2007).
Recently, mitochondrial involvement has been proposed in
two major DNA repair disorders: ataxia-telangiectasia (AT), and
Cockayne syndrome (CS) (Scheibye-Knudsen et al., 2012; Valen-882 Cell 157, 882–896, May 8, 2014 ª2014 Elsevier Inc.tin-Vega et al., 2012). As the power center of cells, mitochondria
are involved in a plethora of metabolic networks and play a signif-
icant role in sustaining the life and health of humans (Green et al.,
2011). Neurons may be particularly vulnerable to mitochondrial
alterations because of their high energy demands. Accordingly,
mitochondrial dysfunction has been proposed to underlie
numerous neurodegenerative diseases. Mitochondrial alterations
may therefore represent an attractive explanation for the neuro-
logical phenotype in some DNA repair disorders. However, in
the case ofCSandAT, themechanisms leading fromaDNA repair
defect to mitochondrial dysfunction have been unclear. Because
mitochondria are involved in a largenumber of processes, defects
in a variety of pathways could lead to secondary mitochondrial
alteration. To address this, we recently developed an in silico
method to screen potential diseases for mitochondrial involve-
ment using a clinical database, http://www.mitodb.com (Schei-
bye-Knudsen et al., 2013). We have continuously expanded this
database and screened for knownDNA repair disorderswith neu-
rodegeneration. An unexpected finding was that patients with xe-
rodermapigmentosum (XP)groupA (XPA)hadasignificant clinical
mitochondrial phenotype.
XP is a rare autosomal-recessive disorder characterized
by severe sun sensitivity leading to a greatly increased risk of
UV-induced skin cancers. XPA was the first disorder shown to
be caused by defective DNA repair, laying the foundation for
numerous discoveries and creating a field of research. In addi-
tion to the dermatological ailments, XPA patients often suffer
from various degrees of neurodegeneration with progressive
cerebral and cerebellar atrophy, neuropathy, and sensorineural
hearing loss (DiGiovanna and Kraemer, 2012). The neurological
features in XPA share substantial similarities to what is often
observed in mitochondrial diseases where progressive cere-
bellar degeneration, peripheral neuropathy, and sensorineural
hearing loss are highly prevalent. Notably, the neurological
deficits seen in AT and CS show extensive clinical overlap with
XPA, perhaps indicating a common pathogenesis in these three
disorders (Table S1).
From an aging perspective, mitochondria are particularly
important because it has been proposed that progressive
mitochondrial dysfunction leads to declining cellular function,
tissue decay, and finally death. Indeed, a number of pathways
known to extend lifespan also appear to preserve mitochondrial
function. SIRT1 is a nicotinamide adenine dinucleotide (NAD+)-
dependent deacetylase that regulates longevity, possibly
through maintenance of mitochondrial homeostasis (Mouchir-
oud et al., 2013). Mitochondrial health can, however, be moder-
ated in several ways. Regulation and elimination of reactive
oxygen species (ROS) through antioxidants, augmentation
of mitochondrial DNA repair, and mitochondrial autophagy
(henceforth mitophagy) have all been suggested to be important
mediators of longevity. SIRT1 has been proposed to increase
mitochondrial health through the transcription factor peroxi-
some proliferator-activated receptor-g coactivator 1 a (PGC-
1a), which appears to be important for the regulation of ROS
and mitochondrial biogenesis, particularly in muscle (Lagouge
et al., 2006). In the brain, however, mitophagy has been pro-
posed to be central in maintaining neuronal health (Youle and
van der Bliek, 2012).
We herein report that XPA deficiency leads to mitochondrial
alterations in nematodes, mice, rats, and humans through an in-
hibition of SIRT1. This mechanism appears in the neurodegener-
ative DNA repair disorders XPA, CS, and AT, but not in a related
DNA repair disorder, XP group C (XPC), where neurodegenera-
tion is rarely seen. In XPA, CS, and AT, SIRT1 attenuation leads
to decreased mitophagy through the depression of PGC-1a and
uncoupling protein 2 (UCP2). Importantly, SIRT1 appears to be
inhibited by the activation of the DNA damage sensor poly-
ADP-ribose polymerase-1 (PARP-1). Indeed, we find that the
mitophagic defect in XPA, CS, and AT can be rescued pharma-
cologically using PARP inhibitors or by overexpressing UCP2.
Furthermore, NAD+ precursors are able to rescue the mitochon-
drial defects in XPA cells and extend lifespan in xpa-1 worms,
indicating a possible therapeutic strategy for this disease. We
present a model explaining the mitochondrial defect seen in
XPA, CS, and AT through a previously unknown nuclear-mito-
chondrial crosstalk. We also propose a key role for the longevity
gene SIRT1 in selectivemitophagy, underscoring the importance
of mitochondrial maintenance in brain health and aging.
RESULTS
XPA Deficiency Leads to Mitochondrial Pathology
Using our bioinformatics tool, http://www.mitodb.com, we
reported that CS and AT clustered with known mitochondrial
disease (Scheibye-Knudsen et al., 2013). In pursuing the goal
of understanding how DNA repair leads to neurodegeneration,
we further screened the database for DNA repair-defective dis-
orders with prominent clinical mitochondrial defects. Using the
bioinformatics tools, we found that XPA was predicted to have
a significant mitochondrial involvement, as evidenced by the
clinical phenotypical similarity with other recognized mitochon-
drial diseases (Figure 1; see Table S1, available online, for the
clinical features of XPA, CS, and AT). Hierarchical clustering
based on the prevalence of signs and symptoms revealed that
XPA associates with the two above-mentioned diseases: CS
and AT. XPA, CS, and AT in turn associated with a number of
known mitochondrial diseases (Figure 1A). Interestingly, XPC,which does not have neurological features, did not associate
with the mitochondrial diseases (Figure 1A). The network in Fig-
ure 1B shows how the diseases associate with each other based
on overlapping signs and symptoms. Each dot represents a dis-
ease, and the connecting lines between the diseases represent
shared traits. The more traits that are shared, the closer two
diseases will associate with each other. As can be seen, XPA,
CS, and AT are closely linked with known mitochondrial dis-
eases, whereas XPC does not link with the mitochondrial disor-
ders (Figure 1B). Furthermore, a mitochondrial bar code for XPA
was generated that revealed a dominating red impression, which
indicates substantial mitochondrial involvement, whereas other
DNA repair disorders (XPC, Nijmegen breakage syndrome,
and Bloom syndrome) without neurodegenerative phenotypes
show much less red in the bar code (Figure 1C). In addition,
two quantitative scores were calculated. A mito score of more
than 50 indicates overlap with moremitochondrial than nonmito-
chondrial diseases, whereas a positive score from the support
vector machine (SVM) indicates a likely mitochondrial involve-
ment. In support of a possible mitochondrial dysfunction, XPA
had a mito score of 72 and a SVM score of 0.27 (Figures 1D
and 1E; and further on http://www.mitodb.com).
To gain additional information regarding the pathogenesis in
XPA, we performed gene expressionmicroarray in two XPA-defi-
cient cell lines and their controls: (1) an immortalized XPA patient
cell line reconstituted with wild-type (WT) XPA (XPA+) or an
empty vector (XPA), and (2) a primary human fibroblast
GM969 with stable small hairpin RNA (shRNA) knockdown of
XPA or with scrambled shRNA. We then identified common
alterations in gene expressions between these cell lines as
XPA dependent. A Venn diagram shows an overlap between
the two above-mentioned groups of 755 significantly changed
genes in which 357 were upregulated and 398 were downregu-
lated (Figure 2A). Gene Ontology (GO) pathway analysis de-
tected a number of significantly changed pathways (Figure 2B).
Among the common 16 upregulated pathways between the
cell lines (Figure S1A), 6 pathways were associated with mito-
chondrial metabolism as evidenced by the significant increase
in z ratios. The array analysis thus supports the findings from
the clinical database (Figure 2C).
We next performed a number of in vivo tests to determine
how XPA might affect mitochondrial function. We first measured
overall oxygen consumption rates (OCRs). In addition to the
XPA cells and their complemented control XPA+ cells, three
primary human fibroblasts from XPA patients and their sex-
and age-matched controls were also used for OCR investigation.
All XPA-deficient cell lines showed increasedOCRs compared to
controls, although for one pair (GM4314 versus GM969), the dif-
ference did not reach significance (Figure 2D). To gain further
insight into the potential regulatory role of XPA in mitochondrial
function, additional XPA-deficient cell lines were generated by
stable shRNA knockdown: two primary human fibroblasts
(GM969 and GM1652) and the SH-SY5Y human neuroblastoma
cells reflecting the significant neurological involvement in XPA
patients. Increased oxygen consumption may stem from the
increased ATP consumption. Bymeasuring ATP levels at various
time points after inhibition of glycolysis using 2-deoxyglucose
and oxidative phosphorylation using oligomycin, we found thatCell 157, 882–896, May 8, 2014 ª2014 Elsevier Inc. 883
Figure 1. Patients Suffering from XPA Are Phenotypically Similar to Patients Suffering from Mitochondrial Diseases
(A) Hierarchical clustering of diseases based on the prevalence of clinical parameters using http://www.mitodb.com.
(B) A representation of how XPA, XPC, CS, and AT associate within the disease network. Each dot represents a disease, and the connecting lines represent one or
more shared sign and/or symptom. The shorter and thicker the line, the greater the prevalence of the shared symptoms.
(C) The mitochondrial bar code of XPA, XPC, CS, AT, Nijmegen breakage syndrome, and Bloom syndrome. Each vertical bar represents a sign or symptom that
is shared with another disease in the database. Mitochondrial (red), nonmitochondrial (green), and diseases of unknown pathogenesis (blue) are shown. A
predominantly red bar code will indicate similarities with mitochondrial diseases, whereas green will indicate nonmitochondrial involvement.
(D and E) Themito score (D) and the SVM score (E) of XPA, XPC, CS, and AT as well as two nonmitochondrial diseases (Crouzon syndrome and cystic fibrosis) and
two bona fide mitochondrial disorders (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes [MELAS] and myoclonic epilepsy
associated with ragged-red fibers [MERRF]).
See also Table S1.
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Figure 2. XPA Deficiency Increases Mitochondrial Metabolism, Membrane Potential, and ROS Formation
(A) Venn diagram illustrating the overlap of induced (red, Z score >1.5) and repressed (green, Z score <1.5) genes between two groups of XPA-deficient cells by
microarray (n = 3).
(B) Heatmap of microarray data showing significantly changed GO terms.
(C) Common statistically significantly upregulated mitochondrial pathways in XPA-deficient cells compared with controls. See also Figure S1A.
(D) OCRs in WT (XPA+) and XPA as well as in primary fibroblasts from XPA patients and their age- and sex-matched controls (mean ± SD; n = 3).
(E and F) ATP levels and ATP consumption in XPA-deficient and control cells were detected using a luciferase-based assay after inhibition of ATP production
with oligomycin and 2-deoxyglucose at time zero (0) (mean ± SD; n = 3). Data in (F) were fitted to an exponential decay curve, and half-lives were calculated
(mean ± SD; n = 3).
(G) Flow cytometry was used to measure MMP using tetramethylrhodamine, methyl ester (TMRM) staining, mitochondrial content using MitoTracker Green,
cellular ROS using dihydroethidium, and mitochondrial ROS using MitoSOX (mean ± SD; n = 3). See also Figures S1 and S2.
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Figure 3. XPA Deficiency Impairs Cellular Mitophagy and Sensitizes Cells to Caspase-9-Regulated Apoptosis under Multiple Mitochondrial
Stresses
(A) Cells were treated with mitochondrial toxins for 24 hr, and LC3 was detected by immunoblot in total cell lysates. Rotenone (Rot.) is a mitochondrial complex I
inhibitor, antimycin A is a mitochondrial complex III inhibitor, and FCCP is a mitochondrial uncoupler.
(B) Quantitative values of relative LC3-II levels normalized to actin (mean ± SD; n = 3).
(C) Relative values of mitochondrial content in XPA and XPA+ cells after different treatments using flow cytometry (mean ± SD;, n = 3).
(D and E) Quantification of colocalization of LC3 and p62 (D) or COX-4 and p62 (E) after treatment with mitochondrial toxins as determined by Pearson’s cor-
relation coefficient using confocal microscopy (mean ± SEM; n > 50). See also Figures S4A and S4B.
(legend continued on next page)
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basal ATP levels were decreased and ATP consumption was
increased (Figures 2E and 2F). XPA deficiency also increased
mitochondrial membrane potential (MMP), mitochondrial con-
tent, and both total as well as mitochondrial ROS (Figure 2G).
To control for potential nonspecific effects of the shRNA that
targets the 30 UTR of XPA, a second shRNA that matches the
coding region of XPA was used in the experiment, and the
same results were acquired (Figure S1B). Both shRNAs show
over 90% knockdown efficiency (Figure S1C). Interestingly,
this mitochondrial phenotype is also seen in AT (Figure 2G)
and CS cells (Scheibye-Knudsen et al., 2012). In contrast,
we did not observe this mitochondrial phenotype in XPC
knockdown cells (Figures 2G and S1D). Immunoblots of two
mitochondrial markers, cytochrome c oxidase 4 (COX-4) and
voltage-dependent anion channel (VDAC), as well as immunoflu-
orescence of cells probed with COX-4 confirmed the finding of
an increased mitochondrial content in XPA cells (Figures S2A
and S2B). Because it has been proposed that Cockayne syn-
drome group B (CSB) and ataxia-telangiectasia-mutated (ATM)
cells act within the mitochondrial matrix to regulate mitochon-
drial function (Aamann et al., 2010; Valentin-Vega et al., 2012),
we isolated mitochondria from cells to investigate whether XPA
might be present in this compartment. Although we found trace
amounts of XPA in mitochondria, particularly after oxidative
damage using menadione, these traces were removed by treat-
ing themitochondrial suspension with Proteinase K (Figure S2C).
This indicates that under our conditions, XPA is not significantly
present in the mitochondrial matrix and that the mitochondrial
alterations may be secondary to a nuclear defect.
XPA Deficiency Upregulates Autophagy
Because previous reports showed altered macroautophagy
(hereafter referred to as autophagy) in AT and CS (Scheibye-
Knudsen et al., 2012; Valentin-Vega et al., 2012), we speculated
that an autophagic defect in XPA could explain the increased
mitochondrial content. To address this hypothesis, we examined
the changes in autophagosomes, autolysosomes, and several
autophagy-related proteins. Surprisingly, we detected increased
levels of the LC3-II signal, which indicates increased autophagy
in all four XPA-deficient human cells as well as in rat neurons
subjected to shRNA knockdown of XPA (Figures S3A and
S3B). Increased LC3-II was also detected in CSB and ATM
cells (Figure S3A, right panel). Treatment with the lysosome
inhibitors bafilomycin A1 and chloroquine revealed increased
LC3-II in XPA cells compared with XPA+ cells, indicating that
XPA deficiency may induce autophagosome synthesis (Fig-
ure S3A, first panel). Accordingly, quantification of autophagy
using an monomeric red fluorescent protein (mRFP)-GFP tan-
dem fluorescent-tagged LC3 plasmid (Kimura et al., 2007)
revealed increased numbers of both autophagosomes and auto-
lysosomes compared to controls (Figures S3C–S3E). Further
p62 levels were decreased in XPA comparedwith controls (Fig-(F) Detection of apoptosis using flow cytometry in XPA and XPA+ cells with Ann
right (mean ± SD; n = 3).
(G) Immunoblot of the expression of proteins involved in caspase-8-regulated and
different mitochondrial toxins. See also Figures S3 and S4.ure S3F), indicating increased autophagy (Klionsky et al., 2012).
This was supported by increases in Beclin-1 levels and Atg12-
Atg5 conjugation in XPA cells compared with WT (Figure S3F),
reflecting activation of autophagy (Klionsky et al., 2012). Notably,
these changes were also seen in CSB- and ATM-deficient cells
(Figure S3F). Furthermore, activity of the mechanistic target of
rapamycin complex 1 (mTORC1), which downregulates auto-
phagy, was inhibited as evidenced by the decreased level
of phosphorylated p70S6, a downstream target of mTORC1
(Figure S3F).
Because we observed increased ATP consumption and
increased ROS formation in XPA-deficient cells, we speculated
that AMP-activated protein kinase (AMPK) activation might
be responsible for the increased autophagy. Indeed, increased
phosphorylation of the AMPKa subunit at Thr172 was observed
in XPA-deficient cells compared with XPA+ cells, indicating acti-
vation of AMPK (Figure S3G). Furthermore, XPA cells treated
with either a AMPK phosphorylation inhibitor (dorsomorphin
[DM]) or a ROS scavenger (N-acetyl-L-cysteine [(NAC]) had
lower levels of phosphorylated AMPKa (Figure S3G). This led
to increased mTOR activation as shown by increased p70S6
phosphorylation. Collectively, these results suggest that auto-
phagy induction in XPA deficiency is at least partially attributed
to activation of AMPK and inhibition of mTOR.
XPADeficiency ImpairsMitophagy andDrives Apoptosis
Increased autophagy could, however, not explain the increased
mitochondrial content. We therefore asked whether the mito-
chondrial alterations could be caused by specific defects
in mitophagy. Three mitochondrial toxins were used to induce
mitophagy: rotenone (a mitochondrial complex I inhibitor),
antimycin A1 (a complex III inhibitor), and the mitochondrial un-
coupler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP). Immunoblots revealed that the toxins induced a signifi-
cant increase in LC3-II levels in WT cells, whereas LC3-II levels
decreased in XPA cells, indicating an impaired mitophagic
process in the absence of XPA protein (Figures 3A and 3B).
These findings were substantiated by increased loss of mito-
chondria in control cells compared to XPA cells after treatment
with various mitochondrial toxins that induce mitophagy (Fig-
ure 3C). We then investigated changes in protein colocalization
among autophagy/mitophagy-associated proteins, including
LC3 versus p62, and COX-4 versus p62. As expected, the mito-
chondrial toxins enhanced the colocalization of both LC3 versus
p62 and COX-4 versus p62 in XPA+ cells as measured by
the Pearson’s coefficient, whereas XPA cells showed loss of
colocalization of LC3 versus p62 and COX-4 versus p62 (Figures
3D, 3E, S4A, and S4B), suggesting deficient relocalization of p62
to damaged mitochondria.
Because studies on the crosstalk between autophagy/mitoph-
agy and apoptosis indicate possible opposite roles on cell
viability (Green et al., 2011), we wanted to investigate whetherexin V/PI staining after mitochondrial stressors. Quantification is shown on the
caspase-9-regulated apoptotic pathways in XPA and XPA+ cells exposed to
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Figure 4. XPA Deficiency Suppresses Mitophagy by Upregulation of Mitochondrial Fusion and Cleavage of PINK1
(A–D) XPA and XPA+ cells were treated with 5 mM rotenone or vehicle for 24 hr, and electron microscopy was performed (A). Triangles indicate damaged
mitochondria. Quantification of damaged mitochondria (B), mitochondrial length (C), and mitochondrial diameter (D) is shown (mean ± SD; n = 14, with >150
mitochondria counted per group).
(E) Immunoblot of proteins involved in mitochondrial size regulation. Bax, Bak, Mfn-1, and Mfn-2 participate in mitochondrial fusion, whereas phosphorylation of
DRP1 at Ser616 is involved in mitochondrial fission.
(F) Protein expression of PINK1 and UCP2 levels in XPA-deficient cells and tissues.
(legend continued on next page)
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XPA-deficient cells were more susceptible to apoptosis induced
by mitochondrial toxins than controls. After treatment with the
above-mentioned mitochondrial toxins, XPA-deficient and con-
trol cells were stained with Annexin V/PI and sorted by flow
cytometry. The results revealed that XPA cells were more
susceptible to mitochondrial stress-induced apoptosis as evi-
denced by more early and late apoptotic cells compared to
control cells (Figure 3F). For example, 5 mM rotenone did not
significantly induce apoptosis in control cells, whereas it trig-
gered nearly 15% apoptotic cell death in XPA cells. Further-
more, when exposed to 10 mM FCCP for 24 hr, the fraction of
apoptotic cells increased from 16.5% in XPA+ cells to over
40% in XPA cells. Consistently, protein markers of apoptosis
including cleaved caspase-3 (p17 and p19 fragments) and the
caspase substrate PARP-1were both increased inmitochondrial
stress-exposed XPA cells (Figure 3G). This appeared to be due
to increased mitochondrial apoptosis signaling because we only
detected cleaved caspase-9 (p35 and p37 fragments), and not
cleaved caspase-8, in XPA cells exposed to mitochondrial
stress (Figure 3G). Taken together, these results indicate that
XPA deficiency leads to a shift from mitophagy to apoptosis
under mitochondrial stress.
The Mitophagy Defect in XPA-Deficient Cells Involves
Mitochondrial Hypertrophy and a Voltage-Dependent
Increase in PINK1 Proteolysis
It is generally believed that small fragmented mitochondria
with depolarized MMP are more easily degraded by mitophagy
in a PINK1/Parkin-dependent pathway. Reduction in MMP
facilitates the accumulation of full-length PINK1 on the outer
mitochondrial membrane of damaged mitochondria leading
to Parkin recruitment and initiation of selective mitophagy
(Youle and van der Bliek, 2012). To investigate if mitochondrial
size might be altered, we performed electron microscopy on
XPA+ and XPA that revealed increased amounts of damaged
mitochondria, increased mitochondrial diameter, and increased
mitochondrial length in XPA cells compared to WT cells (Fig-
ures 4A–4D). Because mitochondrial size and fragmentation
are regulated via a balance between fusion and fission, we
next investigated proteins involved in these processes. Specif-
ically, we detected the mitofusion proteins, mitofusin-1 (Mfn-1),
Mfn-2, Bax, and Bak, as well as the mitofission protein dyna-
min-related protein 1 (DRP1). Indeed, both XPA and shXPA
SY5Y cells showed an upregulation of the above-mentioned
mitofusion proteins and a decrease of phosphorylated DRP1
(Ser616), indicating inhibited mitochondrial fission (Figure 4E).
This pattern was also seen in CSB- and ATM-deficient cells
(Figure 4E).
Because PINK1 is retained at the outer mitochondrial mem-
brane of depolarized mitochondria and XPA deficiency led to
hyperpolarization of the membrane, we next investigated the
stability of full-length PINK1 (Wang et al., 2011). As expected,(G) Quantification of (F) showing full-length and cleaved PINK1 normalized to tot
(H) The colocalization between COX-4 and Parkin in XPA and XPA+ cells treate
coefficient (mean ± SD; n = 3; Figure S4D).
(I) Variousmitochondrial parameters in XPA+ and XPA cells after siRNA knockdo
efficiency).we found increased cleaved PINK1 as well as less full-length
PINK1 in XPA-deficient cells compared with controls (Figures
4F and 4G). Because the MMP may be regulated by mitochon-
drial UCPs, we next investigated the protein levels of UCP1,
UCP2, UCP3, and UCP4 (Figure S4C). Immunoblots with purified
mitochondrial fractions from XPA and XPA+ cells revealed that
UCP2 was significantly decreased in XPA cells (Figure 4F).
Furthermore, the same results were also found in two primary fi-
broblasts from XPA patients as well as in primary rat neurons and
human SH-SY5Y cells subjected to XPA shRNA knockdown
(Figures 4F and 4G). Interestingly, CSB- and ATM-deficient cells
also displayed increased cleavage of PINK1 as well as lower
levels of UCP2 (Figures 4F and 4G). Based on this, we predicted
that XPA-deficient cells would be less able to recruit Parkin to
damaged mitochondria after stress. Indeed, mitochondrial
stress with rotenone failed to increase the colocalization of
Parkin and COX-4 in XPA cells, as indicated by no significant
change in the Pearson’s correlation coefficient, whereas it was
increased in control cells (Figures 4H and S4D). To investigate
if the defect in PINK1 stabilization and Parkin recruitment was
contributing to the mitochondrial phenotype, we performed
small interfering RNA (siRNA) knockdown of these two proteins
in XPA and XPA+ cells. This led to an increase in mitochondrial
content, MMP, and ROS production in WT cells only, indicating
that XPA, PINK1, and Parkin are epistatic in the pathogenesis
of the mitochondrial dysfunction (Figures 4I, S4F, and S4G).
These results collectively indicate that XPA, CSB, or ATM
deficiency triggers mitochondrial fusion and hyperpolarization
of the mitochondrial membrane through a downregulation of
UCP2, leading to cleavage of PINK1 and an inability to clear
damaged mitochondria.
The NAD+-SIRT1-PGC-1a Axis Regulates the Expression
of UCP2, which Can Rescue the Mitophagy Defect in
XPA-Deficient Cells
UCP2 upregulation is associated with attenuation of mitochon-
drial ROS production and neuroprotection (Islam et al., 2012).
To investigate whether UCP2 augmentation could rescue the
mitochondrial phenotype in XPA cells, we transiently trans-
fected UCP2 plasmid into cells followed by rotenone treatment.
UCP2 was expressed in XPA cells, leading to less cleaved
PINK1, and more LC3-II after rotenone treatment (lane 2 versus
lane 4 in Figure 5A). UCP2 transfection in XPA cells also
lowered MMP and decreased mitochondrial content and mito-
chondrial ROS (Figure 5B). This effect was also observed in
ATM-deficient cells, where ectopic UCP2 expression led to a
near-complete rescue of the mitochondrial phenotype (Fig-
ure S4E). Accordingly, siRNA knockdown of UCP2 in XPA
and XPA+ cells led to an exacerbation of the mitochondrial
phenotype, particularly in the WT cells (Figures 5B and S5A).
Considering that UCP2 is regulated by the upstream transcrip-
tion factor PGC-1a and that this factor in turn is regulated byal PINK1 (mean ± SD; n = 3).
d with 5 mM rotenone for 24 hr and quantified using the Pearson’s correlation
wn of PINK1 and Parkin (mean ±SD; n = 3; Figures S4F and S4G for knockdown
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Figure 5. The NAD+-SIRT1-PGC1-a Axis Regulates the Expression of UCP2, which Can Rescue the Mitophagy Defect in XPA Cells
(A) XPA and XPA+ cells were transfected with pUCP2 or an empty vector for 2 days and then treated with 1 mM rotenone or vehicle for 24 hr, followed by
immunoblot for proteins as indicated.
(B) XPA and XPA+ cells were transfected with pUCP2, vector, control siRNA, or siRNA-targeting UCP2 for 2 days; subsequently, indicated parameters were
analyzed by flow cytometry (mean ± SEM; n = 3).
(C) Immunoblot of XPA and XPA+ cells after transfection with control siRNA or siRNA-targeting SIRT1 (siSIRT1).
(D) Representative immunoblot of PAR and PARP-1 in XPA and XPA+ cells.
(E) Immunoblot showing expression of PAR and SIRT1 in primary rat neurons with shRNA XPA knockdown or control shRNA.
(F) Immunoblot of three biological replicates (#1–#3) of whole-cell extracts from young (day 1) and old (day 17) xpa-1 mutant and WT (N2) nematodes.
(G and H) Immunoblot of cerebellar protein levels in 2-week-old WT, Csa/, Xpa/, or Csa//Xpa/ (CX) mice (G) and quantification in (H) (mean ± SD; n = 3).
(I) Immunoblot of XPA and XPA+ cells treated with two PARP inhibitors, 3AB (1 mM) and DPQ (10 mM), for 12 hr, followed an additional 24 hr treatment in the
presence of 1 mM rotenone or vehicle.
See also Figure S5.
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SIRT1 (Bai et al., 2011; Lagouge et al., 2006), we measured the
expression level and activity of these two proteins. In XPA cells,
SIRT1 was less expressed, corresponding with an increased
acetylation of its downstream targets, nuclear factor kB (NF-
kB) (p65) and p53, as compared to controls (Figure 5C). In agree-
ment with this, knockdown of SIRT1 by siRNA-downregulated
PGC-1a and UCP2 (lanes 5 and 7 in Figure S5B) led to deficient
mitophagy as demonstrated by lower levels of LC3 signal from a
relative value of 1.5 to the value of 0.8 of control after rotenone
exposure (Figure S5B, lanes 6 and 8). SIRT1 usesNAD+ as a sub-
strate and is regulated by NAD+ levels (Mouchiroud et al., 2013).
Indeed, NAD+ levels were decreased (see below). NAD+ meta-
bolism is intimately tied to the DNA damage responses through
PARP-1 (Bai et al., 2011). PARP-1 acts as an early responder
to DNA damage, where it creates a PAR-polymer using
NAD+ as a substrate. Because XPA is caused by a defect in
DNA repair, we speculated that the decrease in NAD+ may be
due to increased PARP-1 activity. Indeed, this appeared to be
the case (PAR, Figure 5D). Increased PARP activation and
decreased SIRT1 levels were also observed in primary rat
neurons after XPA knockdown (Figure 5E). It has recently been
suggested that age-associated PAR accumulation could be
conserved from nematodes to mammals (Mouchiroud et al.,
2013), and we thus investigated the consequence of XPA defi-
ciency by examining Sir2 (the nematode homolog of mammalian
SIRT1) and PAR levels in C. elegans. Immunoblots were per-
formed on whole-nematode extracts of synchronized adult
1- and 17-day-old xpa-1(ok698) mutants (xpa-1, the nematode
homolog of human XPA) and WT (N2) worms. Consistent with
previous reports (Mouchiroud et al., 2013), PARylation increased
with age in both types of worms. Interestingly, aged xpa-1 nem-
atodes had significantly higher levels of PAR and decreased Sir2
compared with age-matched WT controls (Figure 5F). Because
the neurodegeneration in Xpa/ mice is very mild, we further
investigated the correlation between PARylation and neurode-
generation in Xpa//Csa/ (CX) mice that display early-onset
cerebellar ataxia (Brace et al., 2013), similar to the Xpa//
Csbm/m mice with increased apoptosis of cerebellar external
granular layer neurons (Murai et al., 2001). Here, a dramatic in-
crease in PAR levels was observed (Figures 5G and 5H). The
age-associated increase in PAR levels in XPA deficiency thus
appears to be conserved from worms to mammals and, impor-
tantly, was also found in CSB and ATM cells, but not in XPC
knockdown cells (Figures S5C and S5D). To test whether
PARP activation might be driving the mitochondrial phenotype,
we utilized PARP inhibitors on the XPA cells. Both XPA and
control cells were pretreated for 12 hr with two PARP inhibitors,
3-aminobenzamide (3AB) and 3,4-Dihydro-5-[4-(1-piperidinyl)
butoxyl]-1(2H)-isoquinolinone (DPQ), and then exposed to rote-
none. 3AB and DPQ significantly inhibited PARylation in XPA
cells tested by immunoblot and confocal microscopy (Figures
5I and S5E). Accompanying the downregulation of PAR was an
upregulation of SIRT1 and PGC-1a, and a stimulation of rote-
none-induced mitophagy in XPA cells shown by an increased
LC3-II signal (lane 2 versus lanes 4 and 6 in Figure 5I). These
data support the notion that the DNA repair deficiency in XPA
leads to PARP-1 activation and an attenuated NAD+-SIRT1-
PGC-1a axis resulting in defective mitophagy.PARP Inhibition and NAD+ Precursor Treatment Rescue
the Mitochondrial Phenotype In Vivo
Recent work has suggested that supplementation with the NAD+
precursors nicotinamide riboside (NR) and nicotinamide mono-
nucleotide (NMN)may attenuate the effect of the age-associated
activation of PARP (Canto´ et al., 2012; Mouchiroud et al., 2013).
We therefore treated the cells with NR and NMN as well as the
PARP inhibitor AZD2281 (olaparib). These treatments appeared
to increase PGC-1a levels and led to SIRT1 activation as shown
by decreased acetylation of p53 (Figure 6A). These treatments
also appeared to attenuate the mitochondrial phenotype, as
evident by a decrease in MMP, mitochondrial content, and
cellular and mitochondrial ROS production (Figure 6B). Indeed,
NAD+ levels increased substantially in both XPA-deficient and
WT cells (Figure 6C). To further address the effect of these com-
pounds on the XPA phenotype, we did lifespan studies on WT
(N2) and xpa-1 worms. There was no difference in the NAD+
levels in young adult worms when comparing WT and xpa-1
extracts (Figure 6D). After 7 days in culture, the NR and NMN
treatment significantly increased NAD+ in both genotypes, and
this corresponded with a decrease in PARylation levels (Figures
6D and 6E). Notably, very old worms (day 17) showed signifi-
cantly decreased levels of NAD+, particularly in xpa-1, and this
decrease was rescued to some extent by NR and NMN treat-
ment. These findings corresponded with increased PAR levels
and decreased Sir2 expression (Figure 7E). Because increased
PAR and decreased NAD+ levels are associated with decreased
longevity, we next explored the lifespan of xpa-1 worms. As pre-
viously described by Arczewska et al. (2013), xpa-1 nematodes
had a shorter mean lifespan than WT N2 worms (12.7 versus
14.1 days, respectively, Figures 6F and 6K). Treatment with the
PARP inhibitor AZD2281, NR, and NMN extended the mean life-
span of xpa-1 (xpa-1 AZD2281, 14.6 days; xpa-1 NR, 15.7 days;
and xpa-1 NMN, 14.9 days; Figures 6G–6I), and increased the
lifespan of WT worms, although this latter increase did not reach
significance (N2 AZD2281, 14.2 days; N2 NR, 14.6 days; and N2
NMN, 14.9 days; Figures 6H–6K).
Recent work has shown that short-term treatment with NAD+
precursors rescues the aging phenotype in mouse skeletal mus-
cle (Gomes et al., 2013). A phenotype of the CX mice is death
at weaning if the mice are fed a hard chow (Brace et al., 2013).
We therefore tested if NR supplementation in the drinking water
of the mothers could rescue the death at weaning of the CX
pups. This did not appear to be the case (data not shown),
indicating that either the death at weaning phenotype was unaf-
fected by NR or that the method of NR supplementation in the
water was inadequate. Instead, we investigated the cerebellum,
a target organ in XPA, in 3-month-old CX mice that were fed a
soft palatable chow, which increases survival at weaning (Brace
et al., 2013). We treated the CX mice with 2 weeks of daily sub-
cutaneous NR injections (500mg NR/kg body weight). Strikingly,
this short-term treatment decreased PAR levels, increased
SIRT1 activation (decreased p53 acetylation), led to retention
of full-length PINK1, and increased the expression of UCP2
in the cerebellum from CX double-knockout mice (Figure 7A).
Furthermore, NAD+ levels, MMP, and mitochondrial ROS pro-
duction were normalized by this treatment (Figures 7B–7D).
ATP levels increased significantly in both genotypes after NRCell 157, 882–896, May 8, 2014 ª2014 Elsevier Inc. 891
Figure 6. NAD+ Augmentation Rescues the Mitochondrial and Aging Phenotype in XPA Cells and xpa-1 Worms
(A) Immunoblot of XPA and XPA+ cells treated for 24 hr with the NAD+ precursors NR and NMN or the PARP inhibitor AZD2281.
(B) Mitochondrial parameters of XPA and XPA+ cells treated for 24 hr with NR, NMN, AZD2281, or DPQ (mean ± SEM; n = 3).
(C) NAD+ levels of XPA and XPA+ cells treated for 24 hr with NR, NMN, or AZD2281 (mean ± SEM; n = 3).
(D) NAD+ levels of WT (N2) or xpa-1 mutant worms treated with NR or NMN throughout their lifespan (mean ± SEM; n = 3).
(E) Immunoblot of WT (N2) or xpa-1 mutants treated with NR or NMN throughout their lifespan.
(F–K) Lifespan curves of WT (N2) or xpa-1 mutants treated with NR, NMN, or AZD2281 throughout their lifespan. Kaplan Meyer survival curves were calculated
from populations of 199–491 animals in each group; significance was calculated by the log rank test.
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Figure 7. The NAD+ Precursor NR Can Rescue the Mitochondrial Phenotype of CX Mice In Vivo
(A) Immunoblot of cerebellar proteins in 3-month-oldWT andCXmice treated with saline or NR subcutaneous injections for 2 weeks (500mgNR/kg body weight).
Each lane is a separate mouse.
(B) NAD+ levels in the cerebellum of the mice described in (A) (mean ± SD; n = 4).
(C) The MMP of isolated cerebellar mitochondria from mice described in (A) (mean ± SD; n = 4).
(D) ROS production in isolated cerebellar mitochondria from mice described in (A) (mean ± SD; n = 4).
(E) ATP levels in the cerebellum of mice as described in (A) (mean ± SD; n = 4).
(F) Venn diagram of significantly changed gene in the cerebellum when comparing CX-Saline with WT-saline and CX-NR treated with WT-saline treated (n = 3).
(G) An overview of the significantly changed genes when comparing CX-Saline versus WT-saline and CX-NR versus WT-saline (n = 3).
(H) Principal component analysis of the average Z scores of all the genes in each group (n = 3).treatment (Figure 7E). Because alterations in NAD+ levels ap-
peared to affect the activity of central transcription factors
such as SIRT1, we hypothesized that NR treatment would rescue
the transcriptional differences between WT and CX mice.
Indeed, gene microarray data showed that the cerebellar tran-
scriptome of the CX mice was partially normalized by the NR
treatment. For CX-saline compared with WT-saline, there were
601 significantly changed genes, whereas CX-NR compared
with WT-saline only showed 363 significantly changed genes
(Figures 7F and 7G). Principal component analysis of the entire
unselected gene set revealed great separation of the CX-saline
andWT group on principal component 1 (PC1, x axis, Figure 7H).
There was no difference in CX-saline and WT groups on PC2
(y axis), indicating that PC1 explained the main differences
in the transcriptome between the two genotypes. A potential
normalizing effect of NR treatment on the transcriptome should
therefore be an effect on PC1. Indeed, NR treatment appeared
to drive the entire transcriptome of CX mice toward WT (Fig-ure 7H). PC2 appeared to be an effect of NR that led to changes
independent of the genotype because there was no difference
in this parameter between WT-saline and CX-saline. Taken
together, these data suggest that PARP activation drives an
accelerated aging phenotype in XPA and that pharmacological
intervention with PARP inhibitors or compounds that increase
NAD+ can partially normalize this phenotype.
DISCUSSION
In this study, we present evidence for a mitochondrial involve-
ment in the XPA phenotype through in silico modeling, micro-
array analysis, and a number of functional metabolic assays on
human cells, rat neurons, mice, and worms. Importantly, the
mitochondrial phenotype in XPA appears similar to what is
observed by us and others in AT and CS. This phenotype may
be caused by defective mitophagy due to excessive cleavage
of PINK1 by hyperpolarized mitochondria. These effects mayCell 157, 882–896, May 8, 2014 ª2014 Elsevier Inc. 893
depend upon depression of the NAD+-SIRT1-PGC-1a-UCP2
axis that is triggered by overactivation of the DNA damage
sensor PARP-1. Our findings highlight the importance of mitoph-
agy in neuronal health and provide insight into the neurode-
generative phenotype in XPA, AT, and CS patients, which is
not explained merely by their classic DNA repair functions.
Is XPA a Mitochondrial Disease?
XPA deficiency appears to lead to mitochondrial dysfunction
across species and in a variety of cell types. This indicates that
a DNA repair defect may yield a similar mitochondrial phenotype
in different tissues. In the context of mitochondrial diseases,
defects are often observed in fibroblast cultures from patients,
although the clinical phenotype is most commonly observed in
brain or muscle tissue. The general consensus regarding this
phenomenon is that brain and muscle are particularly prone to
changes in ATP production, and defective mitochondria would
therefore predominantly manifest as neurodegeneration or my-
opathies even though the mitochondrial defect may be present
in all tissues. Similarly, the DNA repair deficiency in XPA, CS,
and AT is presumably present in all tissues. However, in these
disorders, neurodegeneration could be caused by an increased
ATP consumption leading to an inability to meet the energetic
demand of neurons.
Nucleotide excision repair (NER), in which XPA is a central
player, does not take place in mitochondria, and the XPA protein
itself was not found in this compartment. Thus, themitochondrial
dysfunction we observe appears to be secondary to the nuclear
function of XPA. This may be in contrast to what has been
reported for AT and CS where ATM and CSB were present in
mitochondria (Aamann et al., 2010; Valentin-Vega et al., 2012).
Interestingly, the neurodegeneration seen in XPA is often less
severe than what is seen in AT and CS. If ATM and CSA/CSB
act within the mitochondria, a combined nuclear and mitochon-
drial defect could lead to a more severe mitochondrial pheno-
type than what is seen in XPA. However, a possible role of these
proteins in the mitochondria may be separate from their effect
on mitophagy because we observe similar mitophagic defects
in XPA-, CSB-, and ATM-deficient cell lines.
Roles of XPA outside of Nucleotide Excision DNA Repair
Although the XPA protein is primarily involved in NER, evidence
suggests that it has additional roles in the repair of oxidative DNA
lesions. For example, increased ROS levels have been found
in xpa-1 nematodes and Xpa/ mice, and oxidative nucleotide
damage has been shown in the brains of XPA patients (Arczew-
ska et al., 2013; Hayashi et al., 2005; Maria Berra et al., 2013).
Similarly, increased ROS production also exists in CS and AT pa-
tient cells (Scheibye-Knudsen et al., 2012; Valentin-Vega et al.,
2012). Accordingly, it seems that defects in different pathways
of DNA repair may induce the same oxidative stress phenome-
non. In light of our current findings, increased ROS-induced
DNA damage could be a secondary effect of an increased
MMP and decreased UCP2 in these disorders.
XPA has also been implicated in several other cellular pro-
cesses. XPA-deficient cells have decreased levels of retinoic
acid, and treatment of XPA-deficient cells with retinoic acid
rescued the UV sensitivity of these cells through an unknown894 Cell 157, 882–896, May 8, 2014 ª2014 Elsevier Inc.mechanism (Ding et al., 2001). Interestingly, it has been shown
that retinoic acid can alter the mitochondrial function through
increased expression of UCP1 and UCP2 (Rial et al., 1999). In
light of our findings, increasing UCPs may be particularly impor-
tant and could potentially explain the beneficial effect of retinoic
acid in XPA. In addition, XPA has been proposed to be a tran-
scription factor and is recruited to promoters of genes even
in the absence of exogenous damage (Le May et al., 2010).
Because several studies have linked CSB to transcription, it is
possible that the neurological alterations in CS and XPA may
be exacerbated by a transcriptional deficiency. It is, however,
still not clear what molecular function XPA, CSB, and ATMwould
have in transcription, and more research is warranted.
Defective Mitophagy due to Perturbation of the
NAD+-SIRT1-PGC-1a Axis
Excessive ROS and increased ATP consumption may trigger
higher basal autophagy in DNA repair-deficient cells through
AMPK-driven inhibition of mTOR independent of a defect in
mitophagy. AMPK activation could be an adaptive mechanism
relative to PARP activation and PAR recycling that would
increase ATP consumption. In this regard, SIRT1 and UCP2
depression could be a response to meet the increased ATP de-
mand after DNA damage because increasing MMP will lead to
greater mitochondrial ATP output. Under normal circumstances,
DNA repair removes the damage, shuts down PARP, and allows
MMP to return to normal. In XPA, CS, and AT, persistent DNA
damage may lead to continuous activation of PARP, increased
MMP, and, consequently, defective mitophagy. Simultaneously,
the increased ROS production and AMPK activation appear
to drive mTOR inhibition and increase basal autophagy.
Importantly, XPC-deficient cells do not appear to have PARP
activation, perhaps explaining why these patients rarely develop
neurodegeneration.
We find that SIRT1 may have a central role in mitophagy
through regulation of UCP2 via PGC-1a. PGC-1a is particularly
interesting because loss of this central transcription factor leads
to neurodegeneration (Lagouge et al., 2006; St-Pierre et al.,
2006). In support of a role in neuronal health, UCP2 suppresses
mitochondrial ROS production and leads to neuroprotection in a
Parkinson’s disease model (Andrews et al., 2005). This is perti-
nent because evidence suggests that Parkinson’s disease may
be caused by defective mitophagy. Accordingly, the loss of
UCP2, as we observe, leads to mitochondrial hyperpolarization
and increased import, cleavage, and removal of the central mito-
phagic kinase PINK1. A recent study in nematodes showed
increased PARP activation and lower NAD+ levels in aged WT
nematodes, as well as Sir2-dependent lifespan extension by
PARP inhibition, thus supporting the link between PARP-1and
SIRT1 with aging (Mouchiroud et al., 2013). In agreement with
this, we also detected higher PARylation in older than in younger
nematodes. More importantly, we found that the lifespan defect
in xpa-1 worms could be rescued by treatments with both the
NAD+ precursors NR and NMN and through PARP inhibition
using AZD2281 (olaparib). Quite strikingly, only 2 weeks of treat-
ment with NR rescued the mitochondrial phenotype in the cere-
bellum of the CX mice as well as attenuated the transcriptional
changes in this organ. This study thereby adds to the growing
evidence of a highly coordinated nuclear-mitochondrial cross-
talk in the regulation of lifespan and health span.
Conclusions
In closing, we present herein evidence of a mitochondrial
dysfunction in XPA based on in silico algorithms, transcrip-
tomics analysis, and cellular biology. In addition, we describe
a unifying mechanism leading from the causal endogenous
DNA repair defect to mitochondrial and mitophagic dysfunction
in XPA, CS, and AT. Furthermore, we present a pharmacolog-
ical avenue for therapeutic intervention in XPA using NAD+
precursors.
EXPERIMENTAL PROCEDURES
See Extended Experimental Procedures for detailed methods.
Database
Prediction of mitochondrial pathology of XPA was generated using the online
database http://www.mitodb.com (Scheibye-Knudsen et al., 2013).
Detection of Autophagy and Mitophagy
Monitoring autophagy/mitophagy was carried out by detecting LC3-II/actin
ratio, protein levels of different autophagy-associated proteins, and numbers
of autophagic elements (Klionsky et al., 2012). Autophagic flux was measured
using two autophagy inhibitors: bafilomycin A1 (100 nM), and chloroquine
(10 mM). Autophagic elements were detected by transient transfection of cells
with ptfLC3 plasmid (Addgene; ID 21074, deposited by Tamotsu Yoshimori)
and images by confocal microscopy (Eclipse TE-2000e; Nikon). Mitophagy
was induced with three mitochondrial toxins: rotenone, Antimycin A1, and
FCCP. After treatment with indicated doses for 24 hr, cells were harvested
and prepared for western blotting.
Mitochondrial Parameters
MMP, mitochondrial content, and ROS at both cellular and mitochondrial
levels were measured by a BD Accuri C6 flow cytometer as previously
described (Scheibye-Knudsen et al., 2012).
ATP and NAD+/NADH Quantitation
ATP concentration was detected using an ATPlite Luminescence Assay Sys-
tem (PerkinElmer) as per manufacturer’s instruction. Measurement of NAD+/
NADH was performed using a commercial NAD/NADH assay kit (Abcam;
#ab65348) by following the provided protocol.
Worm Studies
Lifespan analysis was performed at 20C for Bristol N2 and xpa-1 (opk698)
mutants grown on classical nematode growth medium (NGM) plates, or
NGM plates supplemented with 500 mMNR, 500 mMNMN, or 100 nM olaparib
(AZD2281) seededwith E. coliOP50 as food source (Fensga˚rd et al., 2010). We
calculated mean, SD of the mean, and p value using the log rank test from a
pooled population of animals.
NR Supplementation on CX Mice
All animal experiments were performed with the approval of the appropriate
institutional animal care and use committee. CX and WT (C57BL/6) mice
3 months of age were given subcutaneous interscapular injections of
500 mg NR/kg body weight/day or the equivalent volume of saline for a
consecutive 14 days at 4:00 pm (Gomes et al., 2013). On day 15, mice were
sacrificed, and half of a cerebellum was harvested for purification of mitochon-
dria, with the left half snap frozen, homogenized, and aliquoted for western
blotting, microarray, and detection of ATP and NAD+. Freshly purified mito-
chondria were used for detection of MMP andmitochondrial ROSwith fluores-
cence-activated cell sorting (FACS).ACCESSION NUMBERS
The microarray GEO accession number for the data reported in this paper is
GSE55486.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.03.026.
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